An update on pharmacotherapy for autism spectrum disorder in children and adolescents

Research output: Contribution to journalArticle

Abstract

Although there is no known efficacious pharmacotherapy for core symptoms of autism spectrum disorder (ASD), psychotropic medications are commonly prescribed for behavioral/emotional symptoms associated with ASD. We reviewed current evidence-based pharmacotherapy options and updates from recent noteworthy studies. RECENT FINDINGS: Atypical antipsychotics, particularly risperidone and aripiprazole, are effective in reducing irritability, stereotypy and hyperactivity. Metabolic adverse events, including weight gain and dyslipidemia, are common. Methylphenidate is effective in reducing attention-deficit hyperactivity disorder (ADHD) symptoms. Atomoxetine and alpha-2 agonists appear effective in reducing ADHD symptoms. Selective serotonin reuptake inhibitors are not effective in improving repetitive behaviors in children with ASD, and frequently cause activating adverse events. Efficacy of antiepileptic drugs is inconclusive. Overall, efficacy and tolerability of pharmacotherapy in children with ASD are less favorable than data seen in typically developing children with similar symptoms. Newer agents, including glutamatergic agents and oxytocin, appear promising albeit with mixed results. SUMMARY: Current evidence-based pharmacotherapy options in children with ASD are very limited, and many have substantial adverse events. Clinicians should use pharmacotherapy as a part of comprehensive treatment, and judiciously weigh risks and benefits. New pharmacotherapy options for core symptoms as well as co-occurring symptoms of ASD are in urgent need.

Original languageEnglish (US)
Pages (from-to)91-101
Number of pages11
JournalCurrent Opinion in Psychiatry
Volume28
Issue number2
DOIs
StatePublished - Mar 6 2015

Fingerprint

Pervasive Child Development Disorders
Drug Therapy
Attention Deficit Disorder with Hyperactivity
Excitatory Amino Acid Agents
Behavioral Symptoms
Methylphenidate
Risperidone
Serotonin Uptake Inhibitors
Child Behavior
Oxytocin
Dyslipidemias
Anticonvulsants
Antipsychotic Agents
Weight Gain

Keywords

  • Autism spectrum disorder
  • children and adolescents
  • drug therapy
  • pediatric
  • pharmacotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

An update on pharmacotherapy for autism spectrum disorder in children and adolescents. / Young, Na; Findling, Robert L.

In: Current Opinion in Psychiatry, Vol. 28, No. 2, 06.03.2015, p. 91-101.

Research output: Contribution to journalArticle

Young, Na; Findling, Robert L. / An update on pharmacotherapy for autism spectrum disorder in children and adolescents.

In: Current Opinion in Psychiatry, Vol. 28, No. 2, 06.03.2015, p. 91-101.

Research output: Contribution to journalArticle

@article{8a1c5afd340e4c2db70e0d1c3c013606,
title = "An update on pharmacotherapy for autism spectrum disorder in children and adolescents",
abstract = "Although there is no known efficacious pharmacotherapy for core symptoms of autism spectrum disorder (ASD), psychotropic medications are commonly prescribed for behavioral/emotional symptoms associated with ASD. We reviewed current evidence-based pharmacotherapy options and updates from recent noteworthy studies. RECENT FINDINGS: Atypical antipsychotics, particularly risperidone and aripiprazole, are effective in reducing irritability, stereotypy and hyperactivity. Metabolic adverse events, including weight gain and dyslipidemia, are common. Methylphenidate is effective in reducing attention-deficit hyperactivity disorder (ADHD) symptoms. Atomoxetine and alpha-2 agonists appear effective in reducing ADHD symptoms. Selective serotonin reuptake inhibitors are not effective in improving repetitive behaviors in children with ASD, and frequently cause activating adverse events. Efficacy of antiepileptic drugs is inconclusive. Overall, efficacy and tolerability of pharmacotherapy in children with ASD are less favorable than data seen in typically developing children with similar symptoms. Newer agents, including glutamatergic agents and oxytocin, appear promising albeit with mixed results. SUMMARY: Current evidence-based pharmacotherapy options in children with ASD are very limited, and many have substantial adverse events. Clinicians should use pharmacotherapy as a part of comprehensive treatment, and judiciously weigh risks and benefits. New pharmacotherapy options for core symptoms as well as co-occurring symptoms of ASD are in urgent need.",
keywords = "Autism spectrum disorder, children and adolescents, drug therapy, pediatric, pharmacotherapy",
author = "Na Young and Findling, {Robert L.}",
year = "2015",
month = "3",
doi = "10.1097/YCO.0000000000000132",
volume = "28",
pages = "91--101",
journal = "Current Opinion in Psychiatry",
issn = "0951-7367",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - An update on pharmacotherapy for autism spectrum disorder in children and adolescents

AU - Young,Na

AU - Findling,Robert L.

PY - 2015/3/6

Y1 - 2015/3/6

N2 - Although there is no known efficacious pharmacotherapy for core symptoms of autism spectrum disorder (ASD), psychotropic medications are commonly prescribed for behavioral/emotional symptoms associated with ASD. We reviewed current evidence-based pharmacotherapy options and updates from recent noteworthy studies. RECENT FINDINGS: Atypical antipsychotics, particularly risperidone and aripiprazole, are effective in reducing irritability, stereotypy and hyperactivity. Metabolic adverse events, including weight gain and dyslipidemia, are common. Methylphenidate is effective in reducing attention-deficit hyperactivity disorder (ADHD) symptoms. Atomoxetine and alpha-2 agonists appear effective in reducing ADHD symptoms. Selective serotonin reuptake inhibitors are not effective in improving repetitive behaviors in children with ASD, and frequently cause activating adverse events. Efficacy of antiepileptic drugs is inconclusive. Overall, efficacy and tolerability of pharmacotherapy in children with ASD are less favorable than data seen in typically developing children with similar symptoms. Newer agents, including glutamatergic agents and oxytocin, appear promising albeit with mixed results. SUMMARY: Current evidence-based pharmacotherapy options in children with ASD are very limited, and many have substantial adverse events. Clinicians should use pharmacotherapy as a part of comprehensive treatment, and judiciously weigh risks and benefits. New pharmacotherapy options for core symptoms as well as co-occurring symptoms of ASD are in urgent need.

AB - Although there is no known efficacious pharmacotherapy for core symptoms of autism spectrum disorder (ASD), psychotropic medications are commonly prescribed for behavioral/emotional symptoms associated with ASD. We reviewed current evidence-based pharmacotherapy options and updates from recent noteworthy studies. RECENT FINDINGS: Atypical antipsychotics, particularly risperidone and aripiprazole, are effective in reducing irritability, stereotypy and hyperactivity. Metabolic adverse events, including weight gain and dyslipidemia, are common. Methylphenidate is effective in reducing attention-deficit hyperactivity disorder (ADHD) symptoms. Atomoxetine and alpha-2 agonists appear effective in reducing ADHD symptoms. Selective serotonin reuptake inhibitors are not effective in improving repetitive behaviors in children with ASD, and frequently cause activating adverse events. Efficacy of antiepileptic drugs is inconclusive. Overall, efficacy and tolerability of pharmacotherapy in children with ASD are less favorable than data seen in typically developing children with similar symptoms. Newer agents, including glutamatergic agents and oxytocin, appear promising albeit with mixed results. SUMMARY: Current evidence-based pharmacotherapy options in children with ASD are very limited, and many have substantial adverse events. Clinicians should use pharmacotherapy as a part of comprehensive treatment, and judiciously weigh risks and benefits. New pharmacotherapy options for core symptoms as well as co-occurring symptoms of ASD are in urgent need.

KW - Autism spectrum disorder

KW - children and adolescents

KW - drug therapy

KW - pediatric

KW - pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84922398484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922398484&partnerID=8YFLogxK

U2 - 10.1097/YCO.0000000000000132

DO - 10.1097/YCO.0000000000000132

M3 - Article

VL - 28

SP - 91

EP - 101

JO - Current Opinion in Psychiatry

T2 - Current Opinion in Psychiatry

JF - Current Opinion in Psychiatry

SN - 0951-7367

IS - 2

ER -